Pristine Surgical LLC
$5.1M 5 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
SK Life Science, Inc.
SK Life Science, Inc. reported $5,125,494.64 across General Payments, Research, and Ownership to 20,538 physicians and teaching hospitals across 21,051 transactions.
- $5.1M Top quartile payer
- All-tracks total
- 21,051 Top 10% volume
- Transactions
- 20,538 Top 10% reach
- Recipients
- −$742.9K
- General Payments vs PY2023
SK Life Science, Inc. reported $5,125,494.64 across all CMS Open Payments tracks (General + Research + Ownership) to 20,538 physicians and teaching hospitals in Program Year 2024 - ranking #270 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,132,490.15, averaging $249.56 per recipient.
How SK Life Science, Inc.'s $5.1M all-tracks total breaks down
SK Life Science, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
B
80/100
Total payments
D
57/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer sk-life-science-inc SK Life Science, Inc.
$5.1M · #270/1,925 · 0.0% industry · PY2024
- TOT $5.1M
- RANK #270
- SHARE 0.0%
- TXN 21,051
- RCP 20,538
- CAT 5
- GEN $2.1M
- ΔGEN −$742.9K
- TOP1 13.2%
- PY 2024
Volume peers
Nearest volume peer: Pristine Surgical LLC ($5.1M)
SK Life Science, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
SK Life Science, Inc.'s CMS-reported General Payments decreased by $742.9K (−25.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SK LIFE SCIENCE, INC.PY2023: SK LIFE SCIENCE, INC.PY2024: SK Life Science, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,875,366.45
- PY2024
- $2,132,490.15
What the Data Shows for SK Life Science, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For SK Life Science, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 5 general-payment categories charted below, "Honoraria" is the largest at $1.2M across 480 transactions, 54.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
SK Life Science, Inc. made 5 types of general payments. "Honoraria" is the largest category at $1.2M, 54.2% of General Payments.
SK Life Science, Inc. reports 5 general-payment categories - the top three are Honoraria (54.2%), Food and Beverage (27.2%), and Consulting Fee (13.1%). The remaining 2 categories make up 5.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How SK Life Science, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $1.2M | 480 | 54.2% |
| Food and Beverage | $580.5K | 19,436 | 27.2% |
| Consulting Fee | $280.0K | 40 | 13.1% |
| Travel and Lodging | $103.4K | 348 | 4.8% |
| Education | $13.4K | 234 | 0.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $584,296.48 (27.4%) of $2,132,490.15 in this company's General Payments records across 5,571 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for SK Life Science, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
William Rosenfeld
$280,489.67 across 46 reported transactions
- 2
Danielle Becker
$130,931.94 across 108 reported transactions
- 3
Kenneth Laxer
$68,500.58 across 52 reported transactions
- 4
Imad Najm
$52,345.82 across 47 reported transactions
- 5
Karen Keough
$52,028.47 across 54 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
SK Life Science, Inc. ranks #270 of 1,925 by total payments (top 14% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,475 of 1,838 by HHI (bottom 20% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Prime Surgical, LLC : $40.5K total payments, HHI 288
- Alimera Sciences, Inc. : $791.8K total payments, HHI 287
- Bioventus LLC : $1.1M total payments, HHI 286
- Mayne Pharma Commercial LLC : $1.3M total payments, HHI 286
- IRRAS USA, Inc. : $15.1K total payments, HHI 285
- True North Surgical Inc : $27.3K total payments, HHI 281
- SK Life Science, Inc. (this company) : $2.1M total payments, HHI 281
- Stemline Therapeutics Inc. : $1.6M total payments, HHI 280
- Agiliti Health, Inc. : $1.8K total payments, HHI 278
- Saluda Medical Americas, Inc. : $1.8M total payments, HHI 278
- American Medical & Dental Supplies,Inc. : $49.7K total payments, HHI 276
- Fidia Pharma USA Inc. : $55.5K total payments, HHI 276
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as SK Life Science, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about SK Life Science, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with SK Life Science, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Intercept Pharmaceuticals, Inc.
$5.1M 13,236 recipients
Compare payment profiles
BrainScope Company, Inc.
$5.1M 25 recipients
Compare payment profiles
ADC Therapeutics America, Inc.
$5.1M 4,269 recipients
Compare payment profiles
Jcbd, LLC
$5.1M 10 recipients
Compare payment profiles
Actelion Pharmaceuticals US, Inc.
$5.2M 31,311 recipients
Compare payment profiles
Put this to use
SK Life Science, Inc. ranks #270 of 1,925 by all-tracks total payments, led by "Honoraria".
- See where SK Life Science, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just SK Life Science, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.